Annual zoledronic acid may be sufficient to prevent bone loss induced by gonadotrophin-releasing hormone agonist treatment in men with prostatic cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1581, 2007-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer

By Mongiat-Artus Pierre   Teillac Pierre  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2171-2179

Informa Healthcare

Access to resources Recommend Favorite

Zoledronic acid a fast fix for AI-induced bone loss

By  

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins

By Ulloa-Aguirre Alfredo   Timossi Carlos  

Reproductive BioMedicine Online, Vol. 1, Iss. 2, 2000-10 ,pp. : 48-62

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone antagonists: will they replace the agonists?

By Felberbaum Ricardo E   Diedrich Klaus  

Reproductive BioMedicine Online, Vol. 6, Iss. 1, 2003-01 ,pp. : 43-53

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action

By Ortmann O   Weiss JM   Diedrich K  

Reproductive BioMedicine Online, Vol. 5, Iss. 3, 2002-11 ,pp. : 1-7

Reproductive Healthcare Ltd

Access to resources Recommend Favorite